Medipattern's B-CAD(R) Increases Diagnostic Accuracy On Small Breast Cancer Lesions By 44%

Main Category: Breast Cancer
Also Included In: MRI / PET / Ultrasound;  Radiology / Nuclear Medicine;  Medical Devices / Diagnostics
Article Date: 08 Oct 2008 - 2:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

The Medipattern Corporation (TSX VENTURE:MKI), a pioneer in the development of medical software solutions that help improve imaging workflow and productivity, is pleased to announce that a study abstract, showing a statistically significant increase in diagnostic accuracy when using B-CAD Version 2 on lesions less than 1 cm in size, has been published in the October 2008 issue of the American Journal of Clinical Oncology.

The study was conducted at the PLA301 Hospital in Beijing, China using the global version of B-CAD Version 2, and reported in the paper: "The Value of Computer-Aided Detection for Breast Ultra-Sonography (B-CAD) in the Diagnosis of Breast Cancer" by principal authors Dr. Jun Lai Li and Dr. Dan Fei Song. The study is based upon 100 confirmed biopsied cases, comparing the diagnostic accuracy of three reading scenarios: a single physician, double reading with two physicians, and a single physician reading with B-CAD. The accuracy of the single physician increased with B-CAD in all categories. The most striking result shows a statistically significant 44 percent improvement in diagnostic accuracy for the single reader with B-CAD V2 on lesions less than 1 cm in size (n equals 9).

"Finding small cancers is a particularly important part of our overall goal to find cancer in its earliest stage while it is still treatable. Yet small cancers present doctors with their greatest challenge as it is one of the main reasons for misdiagnosis. B-CAD can assist doctors in focusing on these easily overlooked important details and increase the detection rate of small breast cancers," notes Dr. Li in the paper. "The study also finds that CAD is a very useful tool for China's current needs; a single doctor with B-CAD can perform as well as two doctors reading together. A single doctor with B-CAD is far more efficient and economical than using our limited skilled resources for double reading."

"We are very honoured that the authors considered CAD a worthy topic for investigation. The results demonstrate the value of B-CAD V2 in making doctors more efficient, more productive and more effective in the diagnosis of breast cancer," stated Jeff Collins, president and CEO of Medipattern. "These results were first shared during NCBC earlier this year. Publication in a major medical journal is a great honour for all of the authors. It further validates that the study was planned and executed with precision; and that the results increase medical understanding - globally. All of us at Medipattern congratulate the authors on their accomplishment. B-CAD V2 is currently available globally outside of the United States and has received Chinese SFDA as well as CE-medical in Europe and of course Canadian CMDCAS."

Upcoming Events:

Medipattern will participate in the following events:

- Society of Diagnostic Medical Sonography (SDMS) Annual Meeting
October 16 to 19 Foxwoods Resort Casino, CT at the GE booth

- China Medical Exposition
October 20 to 24 Beijing, China at the BJEW booth

- Journees Francaises Radiologie
October 24 to 28 Paris, France at the AG Medical Booth

- Radiological Society of North America (RSNA) Annual Meeting
November 30 to December 5 Chicago, IL
at the Medipattern Booth and at the GE Booth

The Medipattern Corporation

Medipattern(R) is a pioneer in the development of medical software solutions that help improve imaging workflow and productivity. Our first-to-market, award-winning B-CAD(R) advances breast ultrasound computer aided detection (CAD) by streamlining workflow and organizing information into a comprehensive patient record. Medipattern uses its Cadenza(TM) CAD Technology to power the digital conversion in medical communications. B-CAD automatically creates fully digital standardized worksheets and reports that make every practice more efficient, productive and ultimately more effective. For more information, please visit the company's website at: http://www.medipattern.com.

Cadenza(TM) is a trademark of the Medipattern Corporation. B-CAD(R) and Medipattern(R) are registered marks of The Medipattern Corporation. BI-RADS(R) is a registered trademark of the American College of Radiology.

Forward-looking statements

This document contains forward-looking statements relating to Medipattern's performance, operations, or business environment. These statements are based on what we believe are reasonable assumptions given currently available information and our understanding of Medipattern's current activities. We have tried, whenever possible, to identify these forward-looking statements using words such as "anticipates,'' "believes,'' "estimates,'' "expects,'' "plans,'' "intends,'' "potential'', and similar expressions. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict or control. A number of factors could cause actual outcomes and results to differ materially from those expressed in forward-looking statements. These factors include but are not limited to those set forth in the Company's corporate filings, (posted at http://www.sedar.com). In addition, these forward-looking statements relate to the date on which they are made. The Company disclaims any intention or obligation to update or revise any forward-looking statements for any reason. Readers should not rely on forward-looking statements.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release and has neither approved nor disapproved of the contents of this release.

Medipattern Corporation